The RAS/RAF/MEK/ERK signaling pathway is overexpressed or mutated in many malignant tumors, while MEK inhibitors can block tumor cell proliferation and induce cell death by inhibiting downstream signaling (47). Here, MAP2K7 is linked to neoplasm.